Lack of Immune Response to Differentiated Cells Derived from Syngeneic Induced Pluripotent Stem Cells

Guha, Prajna; Morgan, John; Mostoslavsky, Gustavo; Rodrigues, Neil P.; Boyd, Ashleigh S.

doi:10.1016/j.stem.2013.01.006

Cited by 330 publications

(241 citation statements)

References 17 publications

Supporting

Mentioning

225

Contrasting

Unclassified

Order By: Relevance

“…120 Studies testing immunogenicity of iPSC-derived, differentiated cells soon followed. Guha et al 121 and Araki et al 122 reported that miPSC-derived differentiated cells do not illicit an immune response after transplantation in syngeneic recipients. Immunogenecity of iPSCs may be reduced by deriving them from less immunogenic somatic cells.…”

Section: Safety Consideration From Ipsc-based Therapiesmentioning

confidence: 99%

Induced Pluripotent Stem Cells for Post–Myocardial Infarction Repair

Lalit

Hei

Raval

et al. 2014

Circulation Research

122

101

View full text Add to dashboard Cite

Coronary artery disease with associated myocardial infarction continues to be a major cause of death and morbidity around the world despite significant advances in therapy. Patients who suffer large myocardial infarctions are at highest risk for progressive heart failure and death, and cell-based therapies offer new hope for these patients. A recently discovered cell source for cardiac repair has emerged as a result of a breakthrough reprogramming somatic cells to induced pluripotent stem cells (iPSCs). The iPSCs can proliferate indefinitely in culture and can differentiate into cardiac lineages including cardiomyocytes, smooth muscle cells, endothelial cells, and cardiac progenitors. Thus large quantities of desired cell products can be generated without being limited by cellular senescence. The iPSCs can be obtained from patients to allow autologous therapy or, alternatively, banks of HLA diverse iPSCs are possible for allogeneic therapy. Preclinical animal studies using a variety of cell preparations generated from iPSCs have shown evidence of cardiac repair. Methodology for the production of clinical grade products from human iPSCs is in place. Ongoing studies of the safety of various iPSC preparations with regard to the risk of tumor formation, immune rejection, induction of arrhythmias, and formation of stable cardiac grafts are needed as the field advances toward the first in man trials of iPSCs post-MI.

show abstract

Section: Safety Consideration From Ipsc-based Therapiesmentioning

confidence: 99%

Induced Pluripotent Stem Cells for Post–Myocardial Infarction Repair

Lalit

Hei

Raval

et al. 2014

Circulation Research

122

101

View full text Add to dashboard Cite

show abstract

“…Current data on the immunogenicity of the PSCs, including autologous iPSCs can be summed at best as debatable and limited. Studies that attempted to test the likelihood of immune rejection have found contradicting results based on the cell types they chose to transplant into the recipient (Zhao et al 2011;Guha et al 2013). Araki et al found that although many syngeneic-iPSC-derivatives showed negligible immunogenicity, iPSC-CMs were aggressively rejected (Araki et al 2013).…”

Section: Present Challengesmentioning

confidence: 99%

Stem cell therapy for cardiac regeneration: hits and misses

Padda

Sequiera

Sareen

et al. 2015

Can. J. Physiol. Pharmacol.

View full text Add to dashboard Cite

Cardiac injury and loss of cardiomyocytes is a causative as well as a resultant condition of cardiovascular disorders, which are the leading cause of death throughout the world. This loss of cardiomyocytes cannot be completely addressed through the currently available drugs being administered, which mainly function only in relieving the symptoms. There is a huge potential being investigated for regenerative and cell replacement therapies through recruiting stem cells of various origins namely embryonic, reprogramming/induction, and adult tissue. These sources are being actively studied for translation to clinical scenarios. In this review, we attempt to discuss some of these promising scenarios, including the clinical trials and the obstacles that need to be overcome, and hope to address the direction in which stem cell therapy is heading.

show abstract

“…Potential risks associated with clinical iPSC applications include the possibility that viral or other agents used for reprogramming could trigger harmful immune or inflammatory responses (Zhao et al, 2011; Guha et al, 2013). The prevention of vector or transgene integration into the host genome or residual transgene expression once reprogramming has been achieved is important in order to avoid such unwanted responses.…”

Section: Treating Human Diseasementioning

confidence: 99%

Cellular reprogramming for understanding and treating human disease

Kanherkar

Bhatia‐Dey

Makarev

et al. 2014

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

In the last two decades we have witnessed a paradigm shift in our understanding of cells so radical that it has rewritten the rules of biology. The study of cellular reprogramming has gone from little more than a hypothesis, to applied bioengineering, with the creation of a variety of important cell types. By way of metaphor, we can compare the discovery of reprogramming with the archeological discovery of the Rosetta stone. This stone slab made possible the initial decipherment of Egyptian hieroglyphics because it allowed us to see this language in a way that was previously impossible. We propose that cellular reprogramming will have an equally profound impact on understanding and curing human disease, because it allows us to perceive and study molecular biological processes such as differentiation, epigenetics, and chromatin in ways that were likewise previously impossible. Stem cells could be called “cellular Rosetta stones” because they allow also us to perceive the connections between development, disease, cancer, aging, and regeneration in novel ways. Here we present a comprehensive historical review of stem cells and cellular reprogramming, and illustrate the developing synergy between many previously unconnected fields. We show how stem cells can be used to create in vitro models of human disease and provide examples of how reprogramming is being used to study and treat such diverse diseases as cancer, aging, and accelerated aging syndromes, infectious diseases such as AIDS, and epigenetic diseases such as polycystic ovary syndrome. While the technology of reprogramming is being developed and refined there have also been significant ongoing developments in other complementary technologies such as gene editing, progenitor cell production, and tissue engineering. These technologies are the foundations of what is becoming a fully-functional field of regenerative medicine and are converging to a point that will allow us to treat almost any disease.

show abstract

Lack of Immune Response to Differentiated Cells Derived from Syngeneic Induced Pluripotent Stem Cells

Cited by 330 publications

References 17 publications

Induced Pluripotent Stem Cells for Post–Myocardial Infarction Repair

Induced Pluripotent Stem Cells for Post–Myocardial Infarction Repair

Stem cell therapy for cardiac regeneration: hits and misses

Cellular reprogramming for understanding and treating human disease

Contact Info

Product

Resources

About